Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 545,508
  • Shares Outstanding, K 233,123
  • Annual Sales, $ 25,380 K
  • Annual Income, $ -169,930 K
  • EBIT $ -62 M
  • EBITDA $ -59 M
  • 60-Month Beta 0.61
  • Price/Sales 6.20
  • Price/Cash Flow N/A
  • Price/Book 6.14

Options Overview Details

View History
  • Implied Volatility 113.30% (-9.35%)
  • Historical Volatility 100.83%
  • IV Percentile 1%
  • IV Rank 2.13%
  • IV High 1,010.24% on 06/27/25
  • IV Low 93.77% on 01/08/26
  • Expected Move (DTE 2) 0.40 (15.37%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 580
  • Volume Avg (30-Day) 784
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 22,754
  • Open Int (30-Day) 20,334
  • Expected Range 2.20 to 3.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.18 +19.27%
on 12/16/25
3.01 -13.62%
on 12/23/25
+0.28 (+12.07%)
since 12/12/25
3-Month
1.36 +91.18%
on 11/05/25
3.07 -15.31%
on 11/17/25
+0.97 (+59.51%)
since 10/14/25
52-Week
0.35 +633.22%
on 01/30/25
3.07 -15.31%
on 11/17/25
+2.20 (+542.45%)
since 01/14/25

Most Recent Stories

More News
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter Preliminary ending 2025 cash and cash equivalents...

IVVD : 2.60 (+11.11%)
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational...

IVVD : 2.60 (+11.11%)
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular...

IVVD : 2.60 (+11.11%)
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8 th Annual Evercore Healthcare Conference...

IVVD : 2.60 (+11.11%)
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platform...

IVVD : 2.60 (+11.11%)
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an...

IVVD : 2.60 (+11.11%)
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter October 2025 ending cash and cash equivalents...

IVVD : 2.60 (+11.11%)
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced...

IVVD : 2.60 (+11.11%)
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company’s REVOLUTION clinical...

IVVD : 2.60 (+11.11%)
Invivyd’s VYD2311 Receives FDA Clearance for Trials

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Invivyd (...

IVVD : 2.60 (+11.11%)

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 2.99
2nd Resistance Point 2.80
1st Resistance Point 2.70
Last Price 2.60
1st Support Level 2.41
2nd Support Level 2.22
3rd Support Level 2.12

See More

52-Week High 3.07
Last Price 2.60
Fibonacci 61.8% 2.03
Fibonacci 50% 1.71
Fibonacci 38.2% 1.39
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar